Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
RBM47 regulates intestinal injury and tumorigenesis by modifying proliferation, oxidative response, and inflammatory pathways
Saeed Soleymanjahi, Valerie Blanc, Elizabeth A. Molitor, David M. Alvarado, Yan Xie, Vered Gazit, Jeffrey W. Brown, Kathleen Byrnes, Ta-Chiang Liu, Jason C. Mills, Matthew A. Ciorba, Deborah C. Rubin, Nicholas O. Davidson
Saeed Soleymanjahi, Valerie Blanc, Elizabeth A. Molitor, David M. Alvarado, Yan Xie, Vered Gazit, Jeffrey W. Brown, Kathleen Byrnes, Ta-Chiang Liu, Jason C. Mills, Matthew A. Ciorba, Deborah C. Rubin, Nicholas O. Davidson
View: Text | PDF
Research Article Gastroenterology Inflammation

RBM47 regulates intestinal injury and tumorigenesis by modifying proliferation, oxidative response, and inflammatory pathways

  • Text
  • PDF
Abstract

RNA-binding protein 47 (RBM47) is required for embryonic endoderm development, but a role in adult intestine is unknown. We studied intestine-specific Rbm47-knockout mice (Rbm47-IKO) following intestinal injury and made crosses into ApcMin/+ mice to examine alterations in intestinal proliferation, response to injury, and tumorigenesis. We also interrogated human colorectal polyps and colon carcinoma tissue. Rbm47-IKO mice exhibited increased proliferation and abnormal villus morphology and cellularity, with corresponding changes in Rbm47-IKO organoids. Rbm47-IKO mice adapted to radiation injury and were protected against chemical-induced colitis, with Rbm47-IKO intestine showing upregulation of antioxidant and Wnt signaling pathways as well as stem cell and developmental genes. Furthermore, Rbm47-IKO mice were protected against colitis-associated cancer. By contrast, aged Rbm47-IKO mice developed spontaneous polyposis, and Rbm47-IKO ApcMin/+ mice manifested an increased intestinal polyp burden. RBM47 mRNA was decreased in human colorectal cancer versus paired normal tissue, along with alternative splicing of tight junction protein 1 mRNA. Public databases revealed stage-specific reduction in RBM47 expression in colorectal cancer associated independently with decreased overall survival. These findings implicate RBM47 as a cell-intrinsic modifier of intestinal growth, inflammatory, and tumorigenic pathways.

Authors

Saeed Soleymanjahi, Valerie Blanc, Elizabeth A. Molitor, David M. Alvarado, Yan Xie, Vered Gazit, Jeffrey W. Brown, Kathleen Byrnes, Ta-Chiang Liu, Jason C. Mills, Matthew A. Ciorba, Deborah C. Rubin, Nicholas O. Davidson

×

Figure 8

Constitutive intestinal Rbm47 deletion mitigates colitis-associated tumorigenesis after AOM/DSS treatment.

Options: View larger image (or click on image) Download as PowerPoint
Constitutive intestinal Rbm47 deletion mitigates colitis-associated tumo...
(A) Top: Representative gross images of colon from Rbm47fl/fl and Rbm47-IKO mice after AOM/DSS treatment. Bottom: H&E-stained section of a colonic polyp (left, scale bar: 250 μm) from a Rbm47fl/fl mouse and polyp count (right) from Rbm47fl/fl and Rbm47-IKO mice after AOM-DSS treatment (mean ± SEM, unpaired t test, n = 12 fl/fl and 15 IKO); **P < 0.01. (B) Immunohistochemical staining intensity for stromal F4/80 (left) and representative F4/80-stained sections (right, scale bar: 25 μm) of dysplastic colonic lesions from AOM/DSS-treated Rbm47fl/fl and Rbm47-IKO mice (mean ± SEM, unpaired t test, n = 5/genotype, 20 fields at original magnification 40× per mouse); *P < 0.05, **P < 0.01. Staining intensity was determined as the ratio of DAPI to hematoxylin optical density. (C) Average abundance of crypt abscess in dysplastic colonic lesions (left) and representative H&E-stained images (right, scale bar: 100 μm) of crypt abscess (yellow arrowhead) within dysplastic colonic lesions from AOM/DSS-treated Rbm47fl/fl and Rbm47-IKO mice (mean ± SEM, unpaired t test, n = 9 fl/fl and 7 IKO, 20 fields at original magnification 20× per mouse); *P < 0.05, **P < 0.01. (D and F) qPCR evaluation of inflammatory genes (D) and Il-33–related genes (F) in dysplastic colonic tissues from AOM/DSS-treated Rbm47fl/fl and Rbm47-IKO mice (mean ± SEM, unpaired t test, n = 5 fl/fl and 6 IKO); *P < 0.05. (E) qPCR evaluation of antioxidant genes in nondysplastic (left) and dysplastic (right) colonic tissues from AOM/DSS-treated Rbm47fl/fl and Rbm47-IKO mice (mean ± SEM, unpaired t test, n = 5 fl/fl and 6 IKO); *P < 0.05, **P < 0.01.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts